PSMA-617

  • PDF / 168,982 Bytes
  • 1 Pages / 595.245 x 841.846 pts (A4) Page_size
  • 114 Downloads / 156 Views

DOWNLOAD

REPORT

1 S

Nephrotoxicity: case report In a study of 29 patients, a patient [age and sex not stated] was described, who developed nephrotoxicity following treatment with PSMA-617 for progressive metastatic prostate cancer with diffuse marrow involvement. The patient underwent radioligand therapy with PSMA-617 [177Lu-PSMA-617]. Subsequently, the patient developed grade 4 nephrotoxicity related to PSMA-617 [route, dosage, duration of treatment to reaction onset and outcome not stated]. Groner D, et al. Radioligand therapy with 177Lu-PSMA-617 in patients with diffuse bone marrow involvement: Safety and efficacy results. Journal of Nuclear Medicine 61 (Suppl. 1): abstr. 1280, May 2020. Available from: URL: http://jnm.snmjournals.org/content/61/supplement_1/1280.abstract?sid=01e8e19e-1fbf-43bb-b283-84a53228aa09 803515104 [abstract]

0114-9954/20/1830-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 14 Nov 2020 No. 1830

Data Loading...